Zomato CEO Deepinder Goyal's health-tech wearable startup Temple has come under renewed scrutiny after hepatologist Dr Cyriac Abby Philips, widely known online as The Liver Doc, called out podcaster Ranveer Allahbadia for publicly endorsing the device without disclosing his financial stake in the company. The dispute, playing out on X (formerly Twitter), has reignited broader questions about the scientific credibility of Temple's claims and the ethics of undisclosed investor promotion.

The Liver Doc's Challenge to Allahbadia

Reacting to a post by Allahbadia — popularly known by his online identity BeerBiceps — in which he defended Temple against critics, Dr Philips pointed directly to a conflict of interest. 'Hello Ranveer, it is also prudent and ethical to disclose your interests,' he wrote in his response on X.

Dr Philips further noted that Allahbadia had participated in Temple's landmark $54 million seed funding round as a prominent angel investor. While the exact percentage of Allahbadia's personal equity has not been publicly specified in regulatory filings, his dual role — as both a vocal public backer and a financial stakeholder — lies at the heart of the transparency concern.

Allahbadia's Defence of Temple

Ranveer Allahbadia pushed back against detractors in a post on X, arguing that critics lacked sufficient information about Temple's underlying research and development to dismiss the technology as unscientific. He maintained that there was not enough evidence available at this stage to conclusively reject Goyal's project, calling for a more measured assessment before forming judgements.

Notably, Allahbadia's involvement with Temple extends beyond public endorsement — he is also a confirmed angel investor in the startup, though the precise details of his shareholding have not been made public.

Who Owns Temple: The Shareholding Breakdown

According to a shareholding breakdown reported by Inc42 Media, Deepinder Goyal holds a 28.59% stake in Temple, making him the company's largest individual shareholder. Among institutional investors, Steadview Capital holds 5.28%, followed by Peak XV Partners at 3.17%, Dharana Fund at 2.9%, and QLT Technology at 2.11%.

The shareholder list also includes several prominent names from India's startup and business ecosystem, among them Akshant Goyal, Vijay Shekhar Sharma, Varun Alagh, Abhiraj Singh Bhal, Kunal Shah, and Raj Shamani. Employee stock ownership plans account for 10% of equity, with other shareholders collectively holding 38.06%.

The Wider Debate on Health-Tech Credibility

The controversy is not merely about one investor's disclosure — it surfaces a recurring tension in India's fast-growing health-tech space, where celebrity and influencer backing can outpace independent scientific validation. Critics argue that wearables making health or diagnostic claims carry a higher burden of proof than conventional consumer gadgets, and that undisclosed financial interests in promotional content can mislead consumers.

This comes amid a broader global conversation about influencer accountability in health and wellness marketing, with regulators in several jurisdictions tightening rules on paid endorsements. Whether Indian regulatory frameworks — including SEBI's guidelines on investment disclosures or the Advertising Standards Council of India's rules on sponsored content — apply to Allahbadia's posts remains an open question.

What Happens Next

Temple has yet to issue a formal response to the scientific criticism or the conflict-of-interest allegations. As the debate grows, observers will watch whether the company publishes peer-reviewed data to substantiate its claims and whether Allahbadia moves to voluntarily disclose his stake in future endorsements. The episode is likely to sharpen scrutiny of how India's startup ecosystem handles influencer-investor overlaps in health-related ventures.